Dr. Porter comes has 15 years of experience in research and development (R&D) of vaccines and biopharmaceuticals. Additionally, Dr. Porter has a proven track record of advancing novel candidates and production platforms from discovery to the clinic including: cell culture based viral vaccines, next-generation reverse genetics platforms, CHO expressed recombinant protein vaccines and RNA vaccines. With senior level management experience in both academia and industry, Dr. Porter brings a unique perspective and ability to provide and implement high quality management of the new CGMP facility. As Head of Drug Substance R&D at Glaxosmithkline (GSK), Dr. Porter led a global technical development team responsible for antigen manufacturing processes development for the GSK Vaccine product portfolio. His R&D expertise includes production and characterization of vaccines, gene therapy vectors, nucleic acid and recombinant protein therapeutics.